Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Congfei Wang

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5048006929. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
19
Papers, trials and grants by year

2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Cancer antigen 125 levels change rule after laparoscopic biopsy and its prognostic value for patients with unresectable pancreatic ductal adenocarcinoma: a ret… Co-author DOI 10.1186/s12876-026-04688-7↗
  2. An exploratory study of serum creatine kinase as a prognostic marker for patients with resectable pancreatic cancer: looking into the relationship with body co… Co-author DOI 10.1186/s12937-025-01084-x↗
  3. The CA125 level postoperative change rule and its prognostic significance in patients with resectable pancreatic cancer. Co-author DOI 10.1186/s12885-023-11346-8↗
  4. Laparoscopic biopsy and staging for locally advanced pancreatic cancer: experiences of 76 consecutive patients in a single institution. Co-author DOI 10.1007/s00423-021-02199-5↗
  5. Effects of ribosomal associated protein hnRNP D in gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2021.09.052↗
  6. Gemcitabine-Resistance Reversion of Cucurmosin in Human Pancreatic Cancer Cells Co-author DOI 10.21203/rs.3.rs-722308/v1↗
  7. Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective,… First author DOI 10.1136/bmjopen-2020-039900↗
  8. Chemotherapeutic efficacy of cucurmosin for pancreatic cancer as an alternative of gemcitabine: a comparative metabolomic study. First author DOI 10.21037/gs-20-202↗
  9. Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression. Co-author DOI 10.3892/or.2014.3599↗
  10. PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug. Co-author DOI 10.1097/mpa.0000000000000087↗
  11. Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-β signalling pathway. First author DOI 10.1016/s1734-1140(13)71046-6↗
  12. Cucurmosin kills human pancreatic cancer SW-1990 cells in vitro and in vivo. First author DOI 10.2174/18715206113139990109↗

Closest collaborators

The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianchao Lin · 4 shared papers, 2021–2026 · strength 0.89
  2. Ronggui Lin · 4 shared papers, 2021–2026 · strength 0.89
  3. Fengchun Lu · 4 shared papers, 2021–2026 · strength 0.89
  4. Heguang Huang · 7 shared papers, 2013–2025 · strength 0.85
  5. Cong Chen · 2 shared papers, 2025–2026 · strength 0.56
  6. Heguang Huang · 3 shared papers, 2013–2021 · strength 0.51
  7. Xin Luo · 2 shared papers, 2023–2026 · strength 0.51
  8. Jieming Xie · 6 shared papers, 2013–2021 · strength 0.49
  9. Tianhong Teng · 2 shared papers, 2020–2025 · strength 0.35
  10. Yue Wu · 1 shared paper, 2026 · strength 0.32
  11. Minghuang Chen · 4 shared papers, 2013–2020 · strength 0.24
  12. Rong Zheng · 1 shared paper, 2020 · strength 0.12
  13. Xiaobo Li · 1 shared paper, 2020 · strength 0.12
  14. Benhua Xu · 1 shared paper, 2020 · strength 0.12
  15. Heguang Huang · 1 shared paper, 2020 · strength 0.11
  16. Pengfei Guo · 1 shared paper, 2020 · strength 0.11
  17. Binbin Wei · 1 shared paper, 2020 · strength 0.11
  18. Jianghua Feng · 1 shared paper, 2020 · strength 0.11
  19. Weiwei Zhang · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.